Global Regenerative Medicine Market by Technology (Cellular Therapy, Gene Therapy, Tissue Engineering, and Exosome Therapeutics), By Source (Autologous and Allogenic), By Application (Dermatology, Musculoskeletal, Oncology, Cardiovascular, Neurology, Hematology & Immunology, and Others), By End-Users (Hospitals, Ambulatory surgery centers (ASCs), Clinics and Others), and By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)-Global forecast from 2020-2027
Global Regenerative Medicine Market expected to thrust by the rise in diseases related to aging and growing chronic diseases.
The global Regenerative Medicine Market likely to grow with CAGR 10.5% in the forecast period from 2020-2027, owing to the rising government investments in regenerative medicine. Additionally, the spread of chronic diseases and the increasing elderly population will augment the global regenerative medicine market in the upcoming period. According to the International Agency for Research on Cancer (IARC), the global cancer burden estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2019. Globally, the total number of people who are alive within five years of a cancer diagnosis is estimated to be 43.8 million.
According to WHO, the proportion of the burden of non-communicable diseases expected to increase to 57% by 2020. Almost half of the total chronic disease deaths are attributable to cardiovascular diseases, obesity, and diabetes. It has projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and that 71% of deaths due to ischaemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. The growing application of regenerative medicine to address the rising prevalence of diseases such as Alzheimer's disease, Parkinson's disease, diabetes, heart disease, kidney failure, osteoporosis, and spinal cord injury projected to influence the global regenerative medicine market.
Impact of COVID-19 on Global Regenerative medicine market
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. COVID-19 declared as a pandemic on March 11, 2020 by The World Health Organization (WHO). In many economies across diverse domains, this pandemic has disrupted development. In the initial phase of the forecast period, the COVID-19 epidemic will affect the demand for regenerative medicine. The regenerative medicine market is expected to register a certain decline during the forecast period due to national lockdowns, denied wound care facilities, cancelled or delayed elective procedures, and rising skin injuries in COVID-19 medical care providers.
Technology Overview in the Global Regenerative Medicine Market
Based on Technology, the global Regenerative Medicine Market categorized into Cellular Therapy, Gene Therapy, Tissue Engineering, and Exosome Therapeutics. The Cellular Therapy segment accounted for 49.55% market share in 2019 and is expected to dominate the market during the forecast period, 2020-2027. Owing to the growing application of cellular therapy for replacing the tissues and cells to treat various conditions, including arthritis, spinal cord injury, and Parkinson's disease, among others.
Source Overview in the Global Regenerative Medicine Market
Based on the Source, the Global Regenerative Medicine Market classified into Autologous and Allogenic. The Autologous segment estimated to exhibit 62.35% market share in 2019 and is projected to dominate the market, 2020-2027. Due to the minimization of risks from systemic immunological reactions, bio-incompatibility, and disease transmission.
Application Overview in the Global Regenerative Medicine Market
Based on the application, the Global Regenerative Medicine Market segregated into Dermatology, Musculoskeletal, Oncology, Cardiovascular, Neurology, Hematology & Immunology, and Others. The oncology segment witnessed to exhibit 44.65% market share in 2019 and expected to lead the market in the estimated period, 2020-2027, owing to surge in cancer affected population resulted in the implementation of efficient cancer treatment options.
End-User Overview in the Global Regenerative Medicine Market
Based on End-user, the Global Regenerative Medicine market segregated into Hospitals, Ambulatory surgery centers (ASCs), Clinics, and Others. The Hospital segment generated the highest revenue with 52.46% market in 2018 and anticipated to dominate the market over the forecast period 2019-2027 attributable to the hospitals form a partnership with regenerative medicine manufacturing companies to provide cell therapy and tissue scaffolds to improve patient care and treatment.
Regional Overview in the Global Regenerative Medicine Market
By geography, the Global Regenerative Medicine Market segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America anticipated to exhibit 42.75% market share in 2019 and estimated to generate USD 67.87 Billion revenue by 2027 owing to the increasing prevalence of diseases, such as cancer and diabetes coupled with the availability of advanced technologies & the presence of research institutes and the rising initiatives by government and private organizations.
Global Regenerative Medicine Market: Competitive Landscape
Companies such as Integra LifeSciences Corporation, MiMedx Group, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., Stryker Corporation, Zimmer Biomet Holdings Inc., Medtronic Plc., Athersys Inc., US Stem Cell, Organogenesis Inc., Acelity Holdings Inc., Isto Biologics, Cryolife Inc. and Baxter are the key players in the Global Regenerative Medicine Market.
The global Regenerative Medicine Market likely to grow with CAGR 10.5% in the forecast period from 2020-2027, owing to the rising government investments in regenerative medicine. Additionally, the spread of chronic diseases and the increasing elderly population will augment the global regenerative medicine market in the upcoming period. According to the International Agency for Research on Cancer (IARC), the global cancer burden estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2019. Globally, the total number of people who are alive within five years of a cancer diagnosis is estimated to be 43.8 million.
According to WHO, the proportion of the burden of non-communicable diseases expected to increase to 57% by 2020. Almost half of the total chronic disease deaths are attributable to cardiovascular diseases, obesity, and diabetes. It has projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and that 71% of deaths due to ischaemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. The growing application of regenerative medicine to address the rising prevalence of diseases such as Alzheimer's disease, Parkinson's disease, diabetes, heart disease, kidney failure, osteoporosis, and spinal cord injury projected to influence the global regenerative medicine market.
Impact of COVID-19 on Global Regenerative medicine market
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. COVID-19 declared as a pandemic on March 11, 2020 by The World Health Organization (WHO). In many economies across diverse domains, this pandemic has disrupted development. In the initial phase of the forecast period, the COVID-19 epidemic will affect the demand for regenerative medicine. The regenerative medicine market is expected to register a certain decline during the forecast period due to national lockdowns, denied wound care facilities, cancelled or delayed elective procedures, and rising skin injuries in COVID-19 medical care providers.
Technology Overview in the Global Regenerative Medicine Market
Based on Technology, the global Regenerative Medicine Market categorized into Cellular Therapy, Gene Therapy, Tissue Engineering, and Exosome Therapeutics. The Cellular Therapy segment accounted for 49.55% market share in 2019 and is expected to dominate the market during the forecast period, 2020-2027. Owing to the growing application of cellular therapy for replacing the tissues and cells to treat various conditions, including arthritis, spinal cord injury, and Parkinson's disease, among others.
Source Overview in the Global Regenerative Medicine Market
Based on the Source, the Global Regenerative Medicine Market classified into Autologous and Allogenic. The Autologous segment estimated to exhibit 62.35% market share in 2019 and is projected to dominate the market, 2020-2027. Due to the minimization of risks from systemic immunological reactions, bio-incompatibility, and disease transmission.
Application Overview in the Global Regenerative Medicine Market
Based on the application, the Global Regenerative Medicine Market segregated into Dermatology, Musculoskeletal, Oncology, Cardiovascular, Neurology, Hematology & Immunology, and Others. The oncology segment witnessed to exhibit 44.65% market share in 2019 and expected to lead the market in the estimated period, 2020-2027, owing to surge in cancer affected population resulted in the implementation of efficient cancer treatment options.
End-User Overview in the Global Regenerative Medicine Market
Based on End-user, the Global Regenerative Medicine market segregated into Hospitals, Ambulatory surgery centers (ASCs), Clinics, and Others. The Hospital segment generated the highest revenue with 52.46% market in 2018 and anticipated to dominate the market over the forecast period 2019-2027 attributable to the hospitals form a partnership with regenerative medicine manufacturing companies to provide cell therapy and tissue scaffolds to improve patient care and treatment.
Regional Overview in the Global Regenerative Medicine Market
By geography, the Global Regenerative Medicine Market segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America anticipated to exhibit 42.75% market share in 2019 and estimated to generate USD 67.87 Billion revenue by 2027 owing to the increasing prevalence of diseases, such as cancer and diabetes coupled with the availability of advanced technologies & the presence of research institutes and the rising initiatives by government and private organizations.
Global Regenerative Medicine Market: Competitive Landscape
Companies such as Integra LifeSciences Corporation, MiMedx Group, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., Stryker Corporation, Zimmer Biomet Holdings Inc., Medtronic Plc., Athersys Inc., US Stem Cell, Organogenesis Inc., Acelity Holdings Inc., Isto Biologics, Cryolife Inc. and Baxter are the key players in the Global Regenerative Medicine Market.
1. RESEARCH STRATEGIC DEVELOPMENT
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
2. RESEARCH METHODOLOGY
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
3. EXECUTIVE SUMMARY
4. MARKET INSIGHTS
4.1. Supply Chain Analysis
4.2. Economic Factor Analysis
4.2.1. Drivers
4.2.2. Trends
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape
4.4. Competitors & Product Analysis
4.5. Policy & Regulatory Framework
4.6. Company market share analysis, 2019
4.7. Porter’s Five forces analysis
4.8. New Investment Analysis
4.9. PESTEL Analysis
5. GLOBAL REGENERATIVE MEDICINE MARKET OVERVIEW
5.1. Market Size & Forecast, 2016-2027
5.1.1. Global Regenerative Medicine Market By Value (USD)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Technology
5.2.1.1. Cellular Therapy
5.2.1.2. Gene Therapy
5.2.1.3. Tissue Engineering
5.2.1.4. Exosome Therapeutics
5.2.2. By Source
5.2.2.1. Autologous
5.2.2.2. Allogenic
5.2.3. By Application
5.2.3.1. Dermatology
5.2.3.2. Musculoskeletal
5.2.3.3. Oncology
5.2.3.4. Cardiovascular
5.2.3.5. Neurology
5.2.3.6. Hematology & Immunology
5.2.3.7. Others
5.2.4. By End-Users
5.2.4.1. Hospitals
5.2.4.2. Ambulatory surgery centers (ASCs)
5.2.4.3. Clinics
5.2.4.4. Others
5.2.5. By Region
5.2.5.1. North America
5.2.5.2. Europe
5.2.5.3. Asia Pacific
5.2.5.4. South America
5.2.5.5. Middle East & Africa
6. NORTH AMERICA REGENERATIVE MEDICINE MARKET
6.1. North America Regenerative Medicine Market Size & Forecast, 2016-2027
6.1.1. By Value (USD)
6.2. North America Regenerative Medicine Market Estimates & Forecast, 2016-2027 (USD Million)
6.2.1. By Technology
6.2.1.1. Cellular Therapy
6.2.1.2. Gene Therapy
6.2.1.3. Tissue Engineering
6.2.1.4. Exosome Therapeutics
6.2.2. By Source
6.2.2.1. Autologous
6.2.2.2. Allogenic
6.2.3. By Application
6.2.3.1. Dermatology
6.2.3.2. Musculoskeletal
6.2.3.3. Oncology
6.2.3.4. Cardiovascular
6.2.3.5. Neurology
6.2.3.6. Hematology & Immunology
6.2.3.7. Others
6.2.4. By End-Users
6.2.4.1. Hospitals
6.2.4.2. Ambulatory surgery centers (ASCs)
6.2.4.3. Clinics
6.2.4.4. Others
6.2.5. By Country
6.2.5.1. U.S.A
6.2.5.2. Canada
6.2.5.3. Mexico
6.2.6. Company Market Share (Top 3-5)
6.2.7. Economic Impact Study on North America Regenerative Medicine Market
7. EUROPE REGENERATIVE MEDICINE MARKET
7.1. Europe Regenerative Medicine Market Size & Forecast, 2016-2027
7.1.1. By Value (USD)
7.2. Europe Regenerative Medicine Market Estimates & Forecast, 2016-2027 (USD Million)
7.2.1. By Technology
7.2.1.1. Cellular Therapy
7.2.1.2. Gene Therapy
7.2.1.3. Tissue Engineering
7.2.1.4. Exosome Therapeutics
7.2.2. By Source
7.2.2.1. Autologous
7.2.2.2. Allogenic
7.2.3. By Application
7.2.3.1. Dermatology
7.2.3.2. Musculoskeletal
7.2.3.3. Oncology
7.2.3.4. Cardiovascular
7.2.3.5. Neurology
7.2.3.6. Hematology & Immunology
7.2.3.7. Others
7.2.4. By End-Users
7.2.4.1. Hospitals
7.2.4.2. Ambulatory surgery centers (ASCs)
7.2.4.3. Clinics
7.2.4.4. Others
7.2.5. By Country
7.2.5.1. Germany
7.2.5.2. U.K
7.2.5.3. France
7.2.5.4. Italy
7.2.5.5. Netherlands
7.2.5.6. Rest of Europe
7.2.6. Company Market Share (Top 3-5)
7.2.7. Economic Impact Study on Europe Regenerative Medicine Market
8. ASIA PACIFIC REGENERATIVE MEDICINE MARKET
8.1. Asia Pacific Regenerative Medicine Market Size & Forecast, 2016-2027
8.1.1. By Value (USD)
8.2. Asia Pacific Regenerative Medicine Market Estimates & Forecast, 2016-2027 (USD Million)
8.2.1. By Technology
8.2.1.1. Cellular Therapy
8.2.1.2. Gene Therapy
8.2.1.3. Tissue Engineering
8.2.1.4. Exosome Therapeutics
8.2.2. By Source
8.2.2.1. Autologous
8.2.2.2. Allogenic
8.2.3. By Application
8.2.3.1. Dermatology
8.2.3.2. Musculoskeletal
8.2.3.3. Oncology
8.2.3.4. Cardiovascular
8.2.3.5. Neurology
8.2.3.6. Hematology & Immunology
8.2.3.7. Others
8.2.4. By End-Users
8.2.4.1. Hospitals
8.2.4.2. Ambulatory surgery centers (ASCs)
8.2.4.3. Clinics
8.2.4.4. Others
8.2.5. By Country
8.2.5.1. China
8.2.5.2. India
8.2.5.3. Japan
8.2.5.4. Australia
8.2.5.5. South Korea
8.2.5.6. Rest of Asia Pacific
8.2.6. Company Market Share (Top 3-5)
8.2.7. Economic Impact Study on Asia Pacific Regenerative Medicine Market
9. SOUTH AMERICA REGENERATIVE MEDICINE MARKET
9.1. South America Regenerative Medicine Market Size & Forecast, 2016-2027
9.1.1. By Value (USD)
9.2. South America Regenerative Medicine Market estimates & forecast, 2016-2027 (USD Million)
9.2.1. By Technology
9.2.1.1. Cellular Therapy
9.2.1.2. Gene Therapy
9.2.1.3. Tissue Engineering
9.2.1.4. Exosome Therapeutics
9.2.2. By Source
9.2.2.1. Autologous
9.2.2.2. Allogenic
9.2.3. By Application
9.2.3.1. Dermatology
9.2.3.2. Musculoskeletal
9.2.3.3. Oncology
9.2.3.4. Cardiovascular
9.2.3.5. Neurology
9.2.3.6. Hematology & Immunology
9.2.3.7. Others
9.2.4. By End-Users
9.2.4.1. Hospitals
9.2.4.2. Ambulatory surgery centers (ASCs)
9.2.4.3. Clinics
9.2.4.4. Others
9.2.5. By Country
9.2.5.1. Brazil
9.2.5.2. Argentina
9.2.5.3. Rest of South America
9.2.6. Company Market Share (Top 3-5)
9.2.7. Economic Impact Study on South America Regenerative Medicine Market
10. MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET
10.1. Middle East & Africa Market Size & Forecast, 2016-2027
10.1.1. By Value (USD)
10.2. Middle East & Africa Market estimates & forecast, 2016-2027 (USD Million)
10.2.1. By Technology
10.2.1.1. Cellular Therapy
10.2.1.2. Gene Therapy
10.2.1.3. Tissue Engineering
10.2.1.4. Exosome Therapeutics
10.2.2. By Source
10.2.2.1. Autologous
10.2.2.2. Allogenic
10.2.3. By Application
10.2.3.1. Dermatology
10.2.3.2. Musculoskeletal
10.2.3.3. Oncology
10.2.3.4. Cardiovascular
10.2.3.5. Neurology
10.2.3.6. Hematology & Immunology
10.2.3.7. Others
10.2.4. By End-Users
10.2.4.1. Hospitals
10.2.4.2. Ambulatory surgery centers (ASCs)
10.2.4.3. Clinics
10.2.4.4. Others
10.2.5. By Country
10.2.5.1. Saudi Arabia
10.2.5.2. UAE
10.2.5.3. South Africa
10.2.5.4. Rest of Middle East & Africa
10.2.6. Company Market Share (Top 3-5)
10.2.7. Economic Impact Study on Middle East & Africa Regenerative Medicine Market
11. COMPETITOR ANALYSIS
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profiles
11.7.1. Integra LifeSciences Corporation
11.7.2. MiMedx Group, Inc.
11.7.3. AstraZeneca
11.7.4. F. Hoffmann-La Roche Ltd
11.7.5. Merck & Co., Inc.
11.7.6. Pfizer Inc.
11.7.7. Stryker Corporation
11.7.8. Zimmer Biomet Holdings Inc.
11.7.9. Medtronic Plc.
11.7.10. Athersys Inc.
11.7.11. US Stem Cell
11.7.12. Organogenesis Inc.
11.7.13. Acelity Holdings Inc.
11.7.14. Isto Biologics
11.7.15. Cryolife Inc.
11.7.16. Baxter
11.7.17. Other Leading Players
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
2. RESEARCH METHODOLOGY
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
3. EXECUTIVE SUMMARY
4. MARKET INSIGHTS
4.1. Supply Chain Analysis
4.2. Economic Factor Analysis
4.2.1. Drivers
4.2.2. Trends
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape
4.4. Competitors & Product Analysis
4.5. Policy & Regulatory Framework
4.6. Company market share analysis, 2019
4.7. Porter’s Five forces analysis
4.8. New Investment Analysis
4.9. PESTEL Analysis
5. GLOBAL REGENERATIVE MEDICINE MARKET OVERVIEW
5.1. Market Size & Forecast, 2016-2027
5.1.1. Global Regenerative Medicine Market By Value (USD)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Technology
5.2.1.1. Cellular Therapy
5.2.1.2. Gene Therapy
5.2.1.3. Tissue Engineering
5.2.1.4. Exosome Therapeutics
5.2.2. By Source
5.2.2.1. Autologous
5.2.2.2. Allogenic
5.2.3. By Application
5.2.3.1. Dermatology
5.2.3.2. Musculoskeletal
5.2.3.3. Oncology
5.2.3.4. Cardiovascular
5.2.3.5. Neurology
5.2.3.6. Hematology & Immunology
5.2.3.7. Others
5.2.4. By End-Users
5.2.4.1. Hospitals
5.2.4.2. Ambulatory surgery centers (ASCs)
5.2.4.3. Clinics
5.2.4.4. Others
5.2.5. By Region
5.2.5.1. North America
5.2.5.2. Europe
5.2.5.3. Asia Pacific
5.2.5.4. South America
5.2.5.5. Middle East & Africa
6. NORTH AMERICA REGENERATIVE MEDICINE MARKET
6.1. North America Regenerative Medicine Market Size & Forecast, 2016-2027
6.1.1. By Value (USD)
6.2. North America Regenerative Medicine Market Estimates & Forecast, 2016-2027 (USD Million)
6.2.1. By Technology
6.2.1.1. Cellular Therapy
6.2.1.2. Gene Therapy
6.2.1.3. Tissue Engineering
6.2.1.4. Exosome Therapeutics
6.2.2. By Source
6.2.2.1. Autologous
6.2.2.2. Allogenic
6.2.3. By Application
6.2.3.1. Dermatology
6.2.3.2. Musculoskeletal
6.2.3.3. Oncology
6.2.3.4. Cardiovascular
6.2.3.5. Neurology
6.2.3.6. Hematology & Immunology
6.2.3.7. Others
6.2.4. By End-Users
6.2.4.1. Hospitals
6.2.4.2. Ambulatory surgery centers (ASCs)
6.2.4.3. Clinics
6.2.4.4. Others
6.2.5. By Country
6.2.5.1. U.S.A
6.2.5.2. Canada
6.2.5.3. Mexico
6.2.6. Company Market Share (Top 3-5)
6.2.7. Economic Impact Study on North America Regenerative Medicine Market
7. EUROPE REGENERATIVE MEDICINE MARKET
7.1. Europe Regenerative Medicine Market Size & Forecast, 2016-2027
7.1.1. By Value (USD)
7.2. Europe Regenerative Medicine Market Estimates & Forecast, 2016-2027 (USD Million)
7.2.1. By Technology
7.2.1.1. Cellular Therapy
7.2.1.2. Gene Therapy
7.2.1.3. Tissue Engineering
7.2.1.4. Exosome Therapeutics
7.2.2. By Source
7.2.2.1. Autologous
7.2.2.2. Allogenic
7.2.3. By Application
7.2.3.1. Dermatology
7.2.3.2. Musculoskeletal
7.2.3.3. Oncology
7.2.3.4. Cardiovascular
7.2.3.5. Neurology
7.2.3.6. Hematology & Immunology
7.2.3.7. Others
7.2.4. By End-Users
7.2.4.1. Hospitals
7.2.4.2. Ambulatory surgery centers (ASCs)
7.2.4.3. Clinics
7.2.4.4. Others
7.2.5. By Country
7.2.5.1. Germany
7.2.5.2. U.K
7.2.5.3. France
7.2.5.4. Italy
7.2.5.5. Netherlands
7.2.5.6. Rest of Europe
7.2.6. Company Market Share (Top 3-5)
7.2.7. Economic Impact Study on Europe Regenerative Medicine Market
8. ASIA PACIFIC REGENERATIVE MEDICINE MARKET
8.1. Asia Pacific Regenerative Medicine Market Size & Forecast, 2016-2027
8.1.1. By Value (USD)
8.2. Asia Pacific Regenerative Medicine Market Estimates & Forecast, 2016-2027 (USD Million)
8.2.1. By Technology
8.2.1.1. Cellular Therapy
8.2.1.2. Gene Therapy
8.2.1.3. Tissue Engineering
8.2.1.4. Exosome Therapeutics
8.2.2. By Source
8.2.2.1. Autologous
8.2.2.2. Allogenic
8.2.3. By Application
8.2.3.1. Dermatology
8.2.3.2. Musculoskeletal
8.2.3.3. Oncology
8.2.3.4. Cardiovascular
8.2.3.5. Neurology
8.2.3.6. Hematology & Immunology
8.2.3.7. Others
8.2.4. By End-Users
8.2.4.1. Hospitals
8.2.4.2. Ambulatory surgery centers (ASCs)
8.2.4.3. Clinics
8.2.4.4. Others
8.2.5. By Country
8.2.5.1. China
8.2.5.2. India
8.2.5.3. Japan
8.2.5.4. Australia
8.2.5.5. South Korea
8.2.5.6. Rest of Asia Pacific
8.2.6. Company Market Share (Top 3-5)
8.2.7. Economic Impact Study on Asia Pacific Regenerative Medicine Market
9. SOUTH AMERICA REGENERATIVE MEDICINE MARKET
9.1. South America Regenerative Medicine Market Size & Forecast, 2016-2027
9.1.1. By Value (USD)
9.2. South America Regenerative Medicine Market estimates & forecast, 2016-2027 (USD Million)
9.2.1. By Technology
9.2.1.1. Cellular Therapy
9.2.1.2. Gene Therapy
9.2.1.3. Tissue Engineering
9.2.1.4. Exosome Therapeutics
9.2.2. By Source
9.2.2.1. Autologous
9.2.2.2. Allogenic
9.2.3. By Application
9.2.3.1. Dermatology
9.2.3.2. Musculoskeletal
9.2.3.3. Oncology
9.2.3.4. Cardiovascular
9.2.3.5. Neurology
9.2.3.6. Hematology & Immunology
9.2.3.7. Others
9.2.4. By End-Users
9.2.4.1. Hospitals
9.2.4.2. Ambulatory surgery centers (ASCs)
9.2.4.3. Clinics
9.2.4.4. Others
9.2.5. By Country
9.2.5.1. Brazil
9.2.5.2. Argentina
9.2.5.3. Rest of South America
9.2.6. Company Market Share (Top 3-5)
9.2.7. Economic Impact Study on South America Regenerative Medicine Market
10. MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET
10.1. Middle East & Africa Market Size & Forecast, 2016-2027
10.1.1. By Value (USD)
10.2. Middle East & Africa Market estimates & forecast, 2016-2027 (USD Million)
10.2.1. By Technology
10.2.1.1. Cellular Therapy
10.2.1.2. Gene Therapy
10.2.1.3. Tissue Engineering
10.2.1.4. Exosome Therapeutics
10.2.2. By Source
10.2.2.1. Autologous
10.2.2.2. Allogenic
10.2.3. By Application
10.2.3.1. Dermatology
10.2.3.2. Musculoskeletal
10.2.3.3. Oncology
10.2.3.4. Cardiovascular
10.2.3.5. Neurology
10.2.3.6. Hematology & Immunology
10.2.3.7. Others
10.2.4. By End-Users
10.2.4.1. Hospitals
10.2.4.2. Ambulatory surgery centers (ASCs)
10.2.4.3. Clinics
10.2.4.4. Others
10.2.5. By Country
10.2.5.1. Saudi Arabia
10.2.5.2. UAE
10.2.5.3. South Africa
10.2.5.4. Rest of Middle East & Africa
10.2.6. Company Market Share (Top 3-5)
10.2.7. Economic Impact Study on Middle East & Africa Regenerative Medicine Market
11. COMPETITOR ANALYSIS
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profiles
11.7.1. Integra LifeSciences Corporation
11.7.2. MiMedx Group, Inc.
11.7.3. AstraZeneca
11.7.4. F. Hoffmann-La Roche Ltd
11.7.5. Merck & Co., Inc.
11.7.6. Pfizer Inc.
11.7.7. Stryker Corporation
11.7.8. Zimmer Biomet Holdings Inc.
11.7.9. Medtronic Plc.
11.7.10. Athersys Inc.
11.7.11. US Stem Cell
11.7.12. Organogenesis Inc.
11.7.13. Acelity Holdings Inc.
11.7.14. Isto Biologics
11.7.15. Cryolife Inc.
11.7.16. Baxter
11.7.17. Other Leading Players
